# Bevacizumab With or Without Trebananib in Treating Patients With Recurrent Brain Tumors

> **NCT01609790** · PHASE2 · COMPLETED · sponsor: **National Cancer Institute (NCI)** · enrollment: 137 (actual)

## Conditions studied

- Giant Cell Glioblastoma
- Glioblastoma
- Gliosarcoma
- Oligodendroglioma
- Recurrent Brain Neoplasm
- Recurrent Glioblastoma

## Interventions

- **BIOLOGICAL:** Bevacizumab
- **OTHER:** Laboratory Biomarker Analysis
- **OTHER:** Pharmacological Study
- **OTHER:** Placebo Administration
- **BIOLOGICAL:** Trebananib

## Key facts

- **NCT ID:** NCT01609790
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-06-04
- **Primary completion:** 2015-10-02
- **Final completion:** 2022-05-20
- **Target enrollment:** 137 (ACTUAL)
- **Last updated:** 2022-07-21

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01609790

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01609790, "Bevacizumab With or Without Trebananib in Treating Patients With Recurrent Brain Tumors". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT01609790. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*